This supports the notion that in HNSCC, the rate-limiting factor governing EGFR pathway activation is the expression of EGFR ligands (ligand-dependent pathway)20; while in another context such as NSCLC, the EGFR ligand-independent pathway might be prevailing47. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.